While a lot of big companies are trying their best to bring out a perfect vaccine.. Moderna, an American biotechnology company based in Cambridge, Massachusetts claims that they have an 100% effective vaccine against severe covid.
US-based pharma company, Moderna is applying for US and European emergency authorization of its COVID-19 vaccine on monday.
What’s interesting to know is that, The drug company also reported a 100% success rate in preventing severe Covid-19 cases.
Moderna’s is now the second vaccine likely to receive US emergency use authorization this year after Pfizer-BioNTech’s vaccine candidate, which is 95% effective.
The trial results come at a time when the coronavirus pandemic has infected over 63 million people and killed more than 1.4 million across the world.
Moderna’s official statement says,
“A continuous review of safety data is ongoing and no new serious safety concerns have been identified by the company,”
Of the 196 volunteers who contracted COVID-19 in the more than 30,000-person trial, 185 had received a placebo versus 11 who got the vaccine.
The company reported 30 severe cases – all in the placebo group – which means the vaccine was 100% effective at preventing severe cases. The trial included one COVID-19-related death in the placebo group.
Moderna said the vaccine’s efficacy was consistent across age, race, ethnicity and gender demographics.
The 196 cases included 33 adults over 65 and 42 volunteers from racially diverse groups, including 29 Latinos, 6 Blacks, 4 Asian Americans and 3 multiracial participants.
In addition to filing its US application, Moderna said it would apply for conditional approval from the European Medicines Agency, which has already begun a rolling review of data, and would continue to talk with other regulators conducting rolling reviews.
It also announced that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting to review the safety and efficacy data package for mRNA-1273 will likely be scheduled for Thursday, December 17.
Its distribution is expected to be easier than Pfizer’s because while it needs to be stored in a freezer, it does not require the ultra-cold temperature needed by Pfizer’s vaccine.
Moderna plans to start a new trial to test the vaccine in adolescents before the end of the year, followed by another trial in even younger volunteers early in 2021.
Moderna is on track to have about 20 million doses of its vaccine ready to ship in the United States by the end of 2020, enough to inoculate 10 million people.
“By the end of 2020, the Company expects to have approximately 20 million doses of mRNA-1273 available in the U.S. The Company remains on track to manufacture 500 million to 1 billion doses globally in 2021,”
Both the Moderna and Pfizer vaccines rely on a technology called messenger RNA that turns the body’s cells into vaccine-making factories. Messenger RNA has never before been used to develop an approved vaccine.
If you wish to contribute, mail us at firstname.lastname@example.org